Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...